poisar

Stocks · News reference

Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets

Fiscal.ai

Actuate Therapeutics has received a Notice of Allowance from the USPTO for its patent application regarding oral dosage forms of its lead investigational drug, elraglusib.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — ACTUATE THERAPEUTICS, INC. (ACTU)

    Filed: 2026-10-30 AccNo: 0001683168-26-008193 Size: 207 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing